Did any adverse reactions happen during this study?
There were 45.8% of participants who had adverse reactions. This was 38 out of
83 participants.
Durvalumab Durvalumab and Durvalumab and Durvalumab and
alone oleclumab monalizumab danvatirsen
(out of (out of (out of (out of
26 participants) 21 participants) 20 participants) 16 participants)
How many participants had 34.6% (9) 57.1% (12) 50.0% (10) 43.8% (7)
adverse reactions?
How many participants had 3.8% (1) 4.8% (1) 0.0% (0) 6.3% (1)
serious adverse reactions?
How many participants 0.0% (0) 4.8% (1) 0.0% (0) 0.0% (0)
stopped getting study
treatment due to adverse
reactions?
What serious adverse reactions happened during this study?
The table below shows the serious adverse reactions that happened during the
study. There was a total of 3 serious adverse reactions that happened in this study.
Serious adverse reactions
Durvalumab Durvalumab and Durvalumab and Durvalumab
alone oleclumab monalizumab and danvatirsen
(out of (out of (out of (out of
26 participants) 21 participants) 20 participants) 16 participants)
Increase of ketones in a 0.0% (0) 4.8% (1) 0.0% (0) 0.0% (0)
person with diabetes
A disorder of the immune 3.8% (1) 0.0% (0) 0.0% (0) 0.0% (0)
system leading to pain and
inflammation in the joints
Blood loss due to a 0.0% (0) 0.0% (0) 0.0% (0) 6.3% (1)
procedure
No participants died because of adverse reactions.
9 | Clinical Study Results